Table 2. Association of protein expression of actinin-4 and copy number increase in ACTN4 with clinicopathological characteristics of locally advanced pancreatic cancer.
|
Actinin-4 IHC |
ACTN4
FISH |
||||||||
---|---|---|---|---|---|---|---|---|---|---|
Characteristic | Positive | % | Negative | % | P-value* | Positive | % | Negative | % | P-value* |
Median age, years (63.0) |
|
|
|
|
0.159 |
|
|
|
|
0.41 |
<63.0 | 36 | 54.5 | 9 | 36.0 | 9 | 60.0 | 36 | 47.4 | ||
⩾63.0 |
30 |
45.5 |
16 |
64.0 |
|
6 |
40.0 |
40 |
52.6 |
|
Gender |
|
|
|
|
0.6348 |
|
|
|
|
0.02 |
Male | 37 | 56.1 | 16 | 64.0 | 13 | 86.7 | 40 | 52.6 | ||
Female |
29 |
43.9 |
9 |
36.0 |
|
2 |
13.3 |
36 |
47.4 |
|
PS |
|
|
|
|
0.3506 |
|
|
|
|
0.679 |
0 | 21 | 31.8 | 5 | 20.0 | 3 | 20.0 | 23 | 30.3 | ||
1 | 44 | 66.7 | 19 | 76.0 | 12 | 80.0 | 51 | 67.1 | ||
2 |
1 |
1.5 |
1 |
4.0 |
|
0 |
0.0 |
2 |
2.6 |
|
Tumour size |
|
|
|
|
0.8647 |
|
|
|
|
1 |
<37.4 mm | 33 | 50.0 | 12 | 48.0 | 7 | 46.7 | 38 | 50.0 | ||
⩾37.4 mm |
33 |
50.0 |
13 |
52.0 |
|
8 |
53.3 |
38 |
50.0 |
|
Lymph node metastasis |
|
|
|
|
0.4478 |
|
|
|
|
0.059 |
Negative | 48 | 72.7 | 16 | 64.0 | 7 | 46.7 | 57 | 75.0 | ||
Positive |
18 |
27.3 |
9 |
36.0 |
|
8 |
53.3 |
19 |
25.0 |
|
Location of the tumour |
|
|
|
|
0.0379 |
|
|
|
|
0.156 |
Head of pancreas | 31 | 47.0 | 18 | 72.0 | 10 | 66.7 | 33 | 43.4 | ||
Body or tail of pancreas |
35 |
53.0 |
7 |
28.0 |
|
5 |
33.3 |
43 |
56.6 |
|
CA19-9 |
|
|
|
|
0.451 |
|
|
|
|
0.227 |
<1000 U ml−1 | 43 | 65.2 | 19 | 76.0 | 8 | 53.3 | 54 | 71.1 | ||
⩾1000 U ml−1 |
23 |
34.8 |
6 |
24.0 |
|
7 |
46.7 |
22 |
28.9 |
|
Therapy |
|
|
|
|
1 |
|
|
|
|
1 |
CT | 25 | 37.9 | 9 | 36.0 | 6 | 40.0 | 28 | 36.8 | ||
CRT | 41 | 62.1 | 16 | 64.0 | 9 | 60.0 | 48 | 63.2 |
Abbreviations: ACTN4=actinin-4; CRT=chemoradiotherapy; CT=chemotherapy; FISH=fluorescence in situ hybridisation; IHC=immunohistochemistry; PS=Eastern Cooperative Oncology Group Performance Status.
*P-value: Fisher's exact test (two sided). Bold entries indicate statistically significance.